145 results on '"Fred Poordad"'
Search Results
2. Sa1537 HIGH SVR RATES IN 1612 PATIENTS WITH MULTIPLE COMORBID MEDICAL CONDITIONS, INCLUDING ESRD, TREATED WITH HCV DAAS IN COMMUNITY PRACTICE USING A SPECIALIZED PHARMACY TEAM
3. Tu1695 HEALTH OUTCOMES OVER 6 MONTHS IN 907 PATIENTS WITH HEPATIC ENCEPHALOPATHY TREATED IN COMMUNITY PRACTICE USING A SPECIALIZED PHARMACY TEAM
4. SAT-255-Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials
5. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
6. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
7. The development of the diabetes liver fibrosis score: A new prediction model to detect advanced fibrosis in diabetics with nonalcoholic fatty liver disease
8. Regular aspirin use is not protective against advanced fibrosis in type-2 diabetics with biopsy-proven nonalcoholic fatty liver disease
9. Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children
10. THU-194-Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies
11. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
12. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
13. The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology
14. MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure
15. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient
16. 294 - Retreatment of Patients who Failed Glecaprevir/Pibrentasvir Treatment for Hepatitis C Virus Infection
17. Su1468 - Superiority of Avatrombopag to Placebo in Increasing Platelet Counts and Reducing Platelet Transfusions in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedurespooled Analysis of 2 Randomized Phase 3 Studies
18. Su1475 - Consistent Efficacy of Avatrombopag over Placebo in the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures Across Demographic Subgroups - Pooled Results of two Phase 3 Studies
19. The platelet count is declining in American adults in parallel with an increase in risk factors for nonalcoholic fatty liver disease
20. Characterization of patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a large United States cohort
21. Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis
22. Thrombocytopenia associated with chronic liver disease
23. Liver transplant and recurrent disease
24. Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study
25. Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study
26. High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study
27. Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician
28. MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure
29. Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
30. Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH
31. ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis
32. O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks
33. LP07 : Simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: Interim results from the phase II impact study
34. LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study
35. O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)
36. P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis
37. Bone to Total Alkaline Phosphatase Ratios Improve Sensitivity and Specificity of Bone Alkaline Phosphatase Immunoassays
38. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
39. Su1436 Factors Impacting SVR12 for Patients With Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir With Ribavirin in the ALLY-1 Study
40. 604 Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir Treatment of Patients With HCV Genotype 1-Infection Who Failed a Prior Course of DAA Therapy: The QUARTZ-I Study
41. Department of Error
42. Su1416 Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1 - 6 Infection: Results From the SURVEYOR-I and SURVEYOR-II Studies
43. C-Swift Retreatment Final Results: Highly Successful Retreatment of GT1-Infected Patients with 12 Weeks of Elbasvir/Grazoprevir plus Sofosbuvir and Ribavirin after Failure of Short-Duration All-Oral Therapy
44. High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 with or without Ribavirin for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1 HCV Infection
45. High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I)
46. Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection
47. High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection
48. 100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis
49. P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS
50. Tu1018 Sofosbuvir-Based Regimens for Patients With Hepatitis C Virus Genotype 3 Infection: Summary Results From the VALENCE, LONESTAR-2, and ELECTRON-2 Studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.